Based on this premise, we tested whether exogenous RSPO2 could directly increase β-catenin signaling, using a reporter assay and monitoring AXIN2 expression in control and GPR48/LGR4-knockdown thyroid cancer cells. This evidence concerns the gene AXIN2 and thyroid gland carcinoma.